SCHEMBL5416995

SCHEMBL5416995

CN(C)c1ccccc1/C=C/S(=O)(=O)O.NC(=O)c1ccc(Cl)cc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLA P06280 2/20 0.42
FLT1 P17948 4/20 0.41
FLT4 P35916 4/20 0.41
KDR P35968 4/20 0.41
MAPT P10636 5/20 0.41
ALDH1A1 P00352 4/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
KDM4E B2RXH2 3/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
HPGD P15428 2/20 0.41
PKM P14618 1/20 0.41
NFKB1 P19838 1/20 0.41
HTT P42858 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
POLB P06746 2/20 0.39
GPR27 Q9NS67 1/20 0.38
GAA P10253 1/20 0.36
TMEM97 Q5BJF2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4619406 0.86 MAPT (0.45) GLAFLT1FLT4KDRMAPT
SCHEMBL5417239 0.85 MAPT (0.43) GLAFLT1FLT4KDRMAPT
SCHEMBL4620205 0.83 AR (0.49) GLAFLT1FLT4KDRMAPT
SCHEMBL5409229 0.82 CA12 (0.43) FLT1FLT4KDRMAPTALDH1A1
SCHEMBL4618136 0.82 NFE2L2 (0.48) FLT1FLT4KDRMAPTALDH1A1
SCHEMBL5416993 0.81 FLT1 (0.54) FLT1FLT4KDRGPR27
SCHEMBL5417000 0.81 FLT1 (0.54) FLT1FLT4KDRGPR27
SCHEMBL4618986 0.79 PPARG (0.47) GLAFLT1FLT4KDRMAPT
SCHEMBL5420996 0.79 NFE2L2 (0.41) FLT1FLT4KDRMAPTALDH1A1
SCHEMBL27739103 0.79 NFE2L2 (0.41) FLT1FLT4KDRMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7208526-B2 For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US claimed
US-20060270874-A1 Styrylsulfonamides HOFFMANN-LA ROCHE INC. 2006-11-30 US claimed
US-7208526-B2 For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US disclosed
US-20060270874-A1 Styrylsulfonamides HOFFMANN-LA ROCHE INC. 2006-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270874-A1 Styrylsulfonamides STS, SULT1E1, BRCA1 GLA 1872/4885FLT1 4126/4885FLT4 4438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.